Global Cancer Angiogenesis Pipeline Market 2027: Top Key Players Neumedicines, Onyx, Pfizer, TaiRx

The preceding decades have shown the higher incidence and prevalence trends for the cancer. Globally, the scenario is worsening with the mounting number of cancer patients every year.The number of new cancer cases is predicted to rise to by 54% within the next two decades. In economically developing countries, adoption of western lifestyles, such as smoking, poor diet, physical inactivity, and less childbirths, will gradually increase the burden of the treatment. This requirement has made cancer as the most competitive and most studied arena.

Varied classes of chemotherapeutic products are available ranging from monoclonal antibodies, vaccines, immunomodulators, and hormonal therapies to bispecific monoclonal antibodies. Raising the limitations of these therapies are that either they should be given in conjunction with other therapies, require high dose or have got side effects and so on. Pharmacological parameters, overlapping boundaries, cost effectiveness also are the major limitations in these products.

Request For Sample: https://bit.ly/2VpngIQ

One of the major segments of cancer therapy is occupied by the angiogenesis inhibitors. Angiogenesis inhibitors are unique cancer-fighting agents because they block the growth of blood vessels that support tumor growth rather than blocking the growth of tumor cells themselves. Being a new targeted therapy, angiogenesis inhibitors have gained more focus and interest and have optimistic market opportunities. With advent of new and improved technology, angiogenesis inhibitors therapy witnessed a drastic transition and is becoming more acceptable due to its site specific approach. Several regulatory and signaling molecules governing angiogenesis are of interest, including growth factors (e.g. VEGF, PDGF, FGF, EGF), receptor tyrosine kinases, transcription factors such as HIF, as well as molecules involved in MAPK and PI3K signaling.

In some cancers, angiogenesis inhibitors appear to be most effective when combined with additional therapies. There are now several agents available in the market such as bevacizumab (Avastin™) that target the tumor vasculature through different pathways, either by inhibiting formation of the tumor neovasculature or by directly targeting the mature tumor vessels. Because angiogenesis inhibitors work by slowing or stopping tumor growth without killing cancer cells, they are given over a long period.

Therapeutic innovations in various segments have made human acceptance of the new targeted therapies. Now, many of angiogenesis inhibitors are being tested as adjuvant or first-line therapies to determine their efficacy in improving survival. Although majorly angiogenesis inhibitors are used as supportive therapy rather than streamline drugs as they take huge time to even show reasonable results.

An extensive array of compounds is currently in pre-clinical development(Sonepcizumab/Pfizer, KER-1003/Keros, Beperminogene perplasmid/Anges), with many now in the clinic (RG7594/Roche-Phase 1, Darleukin/Philogen-Phase 2, Ofranergene obadenovec/ VBL Therapeutics-Phase 3) and/or achieving FDA approval.

Some of the key players include Acceleron Pharma, Advenchen Laboratories, Allergan, Alnylam Pharmaceuticals, Amgen, Biocon, Celgene, Five Prime Therapeutics, Fujifilm Kyowa Kirin Biologics, Roche, Novartis, Neumedicines, Onyx, Pfizer, TaiRx, TBG Diagnostics, XBiotech.

Request For Table Of Content (TOC): https://bit.ly/2VpngIQ

Hence, it is quite predictable that global market for angiogenesis inhibitors for cancer treatment is expected to register a healthy annual market growth rate. The healthy growth rate can be related to the cumulative effects such as fast technological development, upsurge in the number of incidences of cancer patients, rise in the increasing adverse effects from chemotherapy and increase in the prevalence of cancer patients around the globe.

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products.

Contact Us:
Mr. John Smith
InsightAce Analytic Pvt. Ltd.
Pune, Maharashtra, India
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: https://www.insightaceanalytic.com
Follow Us on LinkedIn @ https://bit.ly/2tBXsgS
Follow Us On Facebook @ https://bit.ly/2H9jnDZ

This release was published on openPR.